Efficacy and safety of once-weekly semaglutide 2·[amount hidden] versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial

What Was Tested

This randomized controlled trial looks at Semaglutide.

For the Spanish translation of the abstract see Supplementary Materials section.

Who Took Part

The abstract describes 4 individuals taking part.

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind, placebo-controlled and parallel-group study.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the individuals and researchers unaware of who received Semaglutide.

Some individuals received a placebo instead of Semaglutide, giving a reference point.

Groups ran in parallel: each of the individuals stayed in one arm throughout.

This trial is registered with ClinicalTrials.gov, NCT05040971, and is complete.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Glucagon-Like Peptides, Hypoglycemic Agents, Obesity, Prediabetic State, Weight Loss and Semaglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 4 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 11 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (The lancet. Diabetes & endocrinology), a journal based in England.

More context: the Semaglutide compound page, all human trials.